Taysha Gene Therapies (TSHA) – Investment Analysts’ Weekly Ratings Changes

by · The Cerbat Gem

Several analysts have recently updated their ratings and price targets for Taysha Gene Therapies (NASDAQ: TSHA):

  • 11/8/2025 – Taysha Gene Therapies was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
  • 11/5/2025 – Taysha Gene Therapies was given a new $8.00 price target on by analysts at JMP Securities.
  • 11/5/2025 – Taysha Gene Therapies had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
  • 11/5/2025 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
  • 11/5/2025 – Taysha Gene Therapies had its price target raised by analysts at Citizens Jmp from $6.00 to $8.00. They now have a “market outperform” rating on the stock.
  • 10/30/2025 – Taysha Gene Therapies had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 10/21/2025 – Taysha Gene Therapies is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $13.00 price target on the stock.
  • 10/17/2025 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
  • 10/17/2025 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
  • 10/8/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 10/2/2025 – Taysha Gene Therapies had its price target raised by analysts at Robert W. Baird from $7.00 to $12.00. They now have an “outperform” rating on the stock.
  • 10/2/2025 – Taysha Gene Therapies had its price target raised by analysts at Needham & Company LLC from $8.00 to $10.00. They now have a “buy” rating on the stock.
  • 9/27/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total value of $646,000.00. Following the transaction, the insider directly owned 1,006,439 shares in the company, valued at approximately $3,250,797.97. This trade represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.78% of the company’s stock.

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Further Reading